Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic
Ali A. Rabaan, Shamsah H. Al-Ahmed, Ranjit Sah, et al.
Annals of Clinical Microbiology and Antimicrobials (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 136

Showing 1-25 of 136 citing articles:

COVID-19 vaccines
Duduzile Ndwandwe, Charles Shey Wiysonge
Current Opinion in Immunology (2021) Vol. 71, pp. 111-116
Open Access | Times Cited: 352
Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm
Ali A. Rabaan, Shamsah H. Al-Ahmed, Javed Muhammad, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 436-436
Open Access | Times Cited: 224
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies
Kuldeep Dhama, Firzan Nainu, Andri Frediansyah, et al.
Journal of Infection and Public Health (2022) Vol. 16, Iss. 1, pp. 4-14
Open Access | Times Cited: 208
Antivirals for COVID-19: A critical review
Andri Frediansyah, Ruchi Tiwari, Khan Sharun, et al.
Clinical Epidemiology and Global Health (2020) Vol. 9, pp. 90-98
Open Access | Times Cited: 175
Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective
Yashpal Singh Malik, Naveen Kumar, Shubhankar Sircar, et al.
Pathogens (2020) Vol. 9, Iss. 7, pp. 519-519
Open Access | Times Cited: 151
Flavonoids: A complementary approach to conventional therapy of COVID-19?
Julia Solnier, Johannes‐Paul Fladerer
Phytochemistry Reviews (2020) Vol. 20, Iss. 4, pp. 773-795
Open Access | Times Cited: 136
Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection
Synat Keam, Dewi Megawati, Shailesh Kumar Patel, et al.
Reviews in Medical Virology (2020) Vol. 30, Iss. 5
Open Access | Times Cited: 84
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions
Christopher J. Day, Benjamin Bailly, Patrice Guillon, et al.
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 74
Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses
Ali A. Rabaan, Shamsah H. Al-Ahmed, Mohammed Garout, et al.
Pathogens (2021) Vol. 10, Iss. 5, pp. 565-565
Open Access | Times Cited: 74
TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target
Gillina F. G. Bezemer, Johan Garssen
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 66
An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic
Sumit Jamwal, Akash Gautam, John D. Elsworth, et al.
Life Sciences (2020) Vol. 257, pp. 118105-118105
Open Access | Times Cited: 68
β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19
Niraj Kumar Jha, Charu Sharma, Hebaallah Mamdouh Hashiesh, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 56
Egypt's COVID-19 Recent Happenings and Perspectives: A Mini-Review
AbdulRahman A. Saied, Asmaa A. Metwally, Norah Madkhali, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 56
Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems
Sunil Shrestha, Januka Khatri, S Shakya, et al.
Drugs & Therapy Perspectives (2021) Vol. 37, Iss. 8, pp. 376-382
Open Access | Times Cited: 46
The Immunopathology of COVID-19 and the Cannabis Paradigm
Nicole Paland, Antonina Pechkovsky, Miran Aswad, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 42
Teachers' Response to Stress, Anxiety and Depression During COVID‐19 Lockdown: What Have We Learned From the Pandemic?
Laura Lacomba‐Trejo, Konstanze Schoeps, Selene Valero‐Moreno, et al.
Journal of School Health (2022) Vol. 92, Iss. 9, pp. 864-872
Open Access | Times Cited: 36
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
Khan Sharun, Ruchi Tiwari, Mohd I. Yatoo, et al.
Narra J (2022) Vol. 2, Iss. 3, pp. e92-e92
Open Access | Times Cited: 36
Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
Rui Ge, Zuyuan Shen, Jian Yin, et al.
SLAS DISCOVERY (2022) Vol. 27, Iss. 2, pp. 79-85
Open Access | Times Cited: 34
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches
Fee Faysal Ahmed, Md. Selim Reza, Md. Shahin Sarker, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0266124-e0266124
Open Access | Times Cited: 29
In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform
Giulia Russo, Marzio Pennisi, Epifanio Fichera, et al.
BMC Bioinformatics (2020) Vol. 21, Iss. S17
Open Access | Times Cited: 43
COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact—an updated review
Youssef A. Attia, Mohamed T. El‐Saadony, Ayman A. Swelum, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 18, pp. 22241-22264
Open Access | Times Cited: 39
Identification of 1H-purine-2,6-dione derivative as a potential SARS-CoV-2 main protease inhibitor: molecular docking, dynamic simulations, and energy calculations
Hossam Nada, Ahmed Elkamhawy, Kyeong Lee
PeerJ (2022) Vol. 10, pp. e14120-e14120
Open Access | Times Cited: 25
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review
Mohd. Iqbal Yatoo, Zeenat Hamid, IZHAR AHMAD RATHER, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 7, pp. 1897-1909
Open Access | Times Cited: 32
COVID-19 and sunlight: Impact on SARS-CoV-2 transmissibility, morbidity, and mortality
Khan Sharun, Ruchi Tiwari, Kuldeep Dhama
Annals of Medicine and Surgery (2021) Vol. 66
Open Access | Times Cited: 32
COVID-19 vaccination campaign in Nepal, emerging UK variant and futuristic vaccination strategies to combat the ongoing pandemic
Ranjit Sah, Asmita Priyadarshini Khatiwada, Sunil Shrestha, et al.
Travel Medicine and Infectious Disease (2021) Vol. 41, pp. 102037-102037
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top